Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Prognostic Impact and Risk Factors of Infections in Patients with Chronic Lymphocytic Leukemia Treated with Ibrutinib

Ibrutinib represents extraordinary progress in the treatment of chronic lymphocytic leukemia (CLL). However, treatment-related adverse events limit the benefit of this agent. This observational, multicenter study focused on the incidence, risk factors, and prognostic impact of infections in 494 pati...

Full description

Bibliographic Details
Main Authors: Francesca Romana Mauro, Diana Giannarelli, Andrea Visentin, Gianluigi Reda, Paolo Sportoletti, Anna Maria Frustaci, Annalisa Chiarenza, Stefania Ciolli, Candida Vitale, Luca Laurenti, Lorenzo De Paoli, Roberta Murru, Massimo Gentile, Gian Matteo Rigolin, Luciano Levato, Annamaria Giordano, Giovanni Del Poeta, Caterina Stelitano, Claudia Ielo, Alessandro Noto, Valerio Guarente, Stefano Molica, Marta Coscia, Alessandra Tedeschi, Gianluca Gaidano, Antonio Cuneo, Robin Foà, Maurizio Martelli, Corrado Girmenia, Giuseppe Gentile, Livio Trentin
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
chronic lymphocytic leukemia
ibrutinib
infection
prognosis
Online Access:https://www.mdpi.com/2072-6694/13/13/3240

Internet

https://www.mdpi.com/2072-6694/13/13/3240

Similar Items